Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL
Status:
Recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
To explore the efficacy and safty of Blinatumomab as a bridge to Allogeneic Hematopoietic
Stem Cell Transplantation in High Risk Precursor B-cell Acute Lymphoblastic Leukemia
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University
Collaborators:
First Affiliated Hospital of Wannan Medical College Fujian Medical University Union Hospital The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School The First People's Hospital of Changzhou Wuxi People's Hospital Zhongda Hospital